{"transactions":[{"id":714858,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714857,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":2.49,"value":39840.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714856,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":1.03,"value":16480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":727902,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:18:45.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1250000,"price":16,"value":20000000.0,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":15042035,"source":{"system":"sec-edgar","filing":"0001012975-26-000564","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000564/form4.xml","form_type":"4"}},{"id":730778,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":2306401,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3673635},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730777,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":1204000,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1917731},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730776,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":5148587,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8200669},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730775,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":13792035,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":13792035,"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":746454,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:19:02.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.06,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-041572","document":"wk-form4_1780949938.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026041572/wk-form4_1780949938.xml","form_type":"4"}},{"id":747685,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T20:25:27.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date"}],"balance_after":90000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001770121-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000177012126000003/primary_doc.xml","form_type":"4"}},{"id":794166,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2681265,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2681265},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794165,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2513686,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2513686},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794164,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":1100000,"price":18,"value":19800000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6294951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794163,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2681265,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5194951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794162,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2513686,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2513686,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":853893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":1,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":3,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20890,"kind":"person","name":"BERNS PAUL L","position":8,"cik":"0001202769","reported_name":"BERNS PAUL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":9,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:34:54.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":488090,"price":25.61,"value":12499984.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP.  Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1426528,"source":{"system":"sec-edgar","filing":"0001012975-26-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000234/form4.xml","form_type":"4"}},{"id":999081,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8313680,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P. (\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":999080,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18503128,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":1012114,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:13.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":1915700,"price":2.61,"value":4999977.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6046907,"source":{"system":"sec-edgar","filing":"0001012975-25-000680","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000101297525000680/form4.xml","form_type":"4"}},{"id":1074902,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:27.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.04,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000049","document":"wk-form4_1754441003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000049/wk-form4_1754441003.xml","form_type":"4"}},{"id":1074901,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:27.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000049","document":"wk-form4_1754441003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000049/wk-form4_1754441003.xml","form_type":"4"}},{"id":1074900,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:27.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":39062,"derivative":{"exercise_price":4.04,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000049","document":"wk-form4_1754441003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000049/wk-form4_1754441003.xml","form_type":"4"}},{"id":1074899,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:27.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000049","document":"wk-form4_1754441003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000049/wk-form4_1754441003.xml","form_type":"4"}},{"id":1077714,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-01T23:19:58.000Z","date":"2025-08-01","kind":"purchase","planned":false,"acquired":true,"shares":3030300,"price":3.3,"value":9999990.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are also members of the investment committee of AVP XII LLC (the \"AVP XII LLC Investment Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Investment Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the other AVP XII LLC Investment Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is also an AVP XII Investment Committee Member and may be deemed to to share the power to direct the disposition and vote of the shares held by ARCH XII.  The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":6230300,"source":{"system":"sec-edgar","filing":"0001062993-25-013462","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299325013462/form4.xml","form_type":"4"}},{"id":1117580,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:39:21.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":80000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-25-004642","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000156218025004642/primarydocument.xml","form_type":"4"}},{"id":1121571,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T22:13:40.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-25-029772","document":"wk-form4_1749161379.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025029772/wk-form4_1749161379.xml","form_type":"4"}},{"id":1287653,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287652,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383731},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287651,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287650,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383730},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287649,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":19933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8483268},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287648,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":789998,"price":18,"value":14219964.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":8313680,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287647,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":1432224,"price":18,"value":25780032.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":18503128,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287646,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":7523682,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":7523682,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287645,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":16006949,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":17070904,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1454469,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T20:12:50.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."}],"balance_after":65000,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-24-005722","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000156218024005722/primarydocument.xml","form_type":"4/A","original_submission_date":"2024-06-07"}},{"id":1477396,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-17T20:41:47.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":2.36,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-24-017220","document":"form4-06172024_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588924017220/form4-06172024_080644.xml","form_type":"4"}},{"id":1479385,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:59:08.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date"}],"balance_after":45000,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-24-000039","document":"wk-form4_1718398741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000039/wk-form4_1718398741.xml","form_type":"4"}},{"id":1485283,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":11924138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392738},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485282,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2336000},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485281,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":3728738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3728738,"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1486385,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:22:42.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":54278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":54278,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":54278},"source":{"system":"sec-edgar","filing":"0001562180-24-004844","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000156218024004844/primarydocument.xml","form_type":"4"}},{"id":1495197,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T16:14:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":10.39,"exercise_date":"2025-05-30","expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-026213","document":"wk-form4_1717431281.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026213/wk-form4_1717431281.xml","form_type":"4"}},{"id":1495196,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-03T16:14:50.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":584148,"source":{"system":"sec-edgar","filing":"0001628280-24-026213","document":"wk-form4_1717431281.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026213/wk-form4_1717431281.xml","form_type":"4"}},{"id":1547695,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":366301,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":366301},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547694,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":201465,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":201465},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547693,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":164835,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":164835},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547692,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":227920,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":227920},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547691,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":454212,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454212},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547690,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":586080,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":586080},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547689,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":424908,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":424908},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547688,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":16,"value":2133328.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering."}],"balance_after":1181766,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547687,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":66667,"price":16,"value":1066672.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reflects shares purchased by ARCH IX in the Issuer's initial public offering."}],"balance_after":683759,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547686,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":1048433,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":1048433,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547685,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":787545,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":828570,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547684,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":589743,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":617092,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1634286,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T22:41:09.000Z","date":"2024-02-15","kind":"purchase","planned":false,"acquired":true,"shares":3200000,"price":6.25,"value":20000000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are also members of the investment committee of AVP XII LLC (the \"AVP XII LLC Investment Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Investment Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the other AVP XII LLC Investment Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is also an AVP XII Investment Committee Member and may be deemed to to share the power to direct the disposition and vote of the shares held by ARCH XII.  The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":3200000,"source":{"system":"sec-edgar","filing":"0001062993-24-003740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299324003740/form4.xml","form_type":"4"}},{"id":1648925,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:46:20.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the other AVP X Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000106299324002842/form4.xml","form_type":"4"}},{"id":1648924,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:46:20.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X).  ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the other AVP X Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000106299324002842/form4.xml","form_type":"4"}},{"id":1648923,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:46:20.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":363637,"price":5.5,"value":2000003.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. In addition to the Reporting Person, Keith Crandell and Clinton Bybee are also managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the other AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to to the extent of any pecuniary interest therein"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":10667387,"source":{"system":"sec-edgar","filing":"0001062993-24-002842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000106299324002842/form4.xml","form_type":"4"}},{"id":1714601,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":1176593,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2321566,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1714600,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":703061,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1387228,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1740990,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":3357,"price":11.98,"value":40216.86,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4131207,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1740989,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":31653,"price":11.75,"value":371922.75,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4127850,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1744258,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":5431,"price":11.75,"value":63814.25,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4096197,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744257,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":11844,"price":11.37,"value":134666.28,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4090766,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744256,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-09","kind":"purchase","planned":false,"acquired":true,"shares":31079,"price":10.53,"value":327261.87,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4078922,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744255,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":23124,"price":11.79,"value":272631.96,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4047843,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744254,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":69127,"price":10.78,"value":745189.06,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4024719,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1747753,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":30192,"price":11.5,"value":347208.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3955592,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747752,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-06","kind":"purchase","planned":false,"acquired":true,"shares":43082,"price":11.55,"value":497597.1,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3925400,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747751,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-03","kind":"purchase","planned":false,"acquired":true,"shares":22420,"price":11.38,"value":255139.6,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3882318,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1771636,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-29","kind":"purchase","planned":false,"acquired":true,"shares":34560,"price":13.98,"value":483148.8,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.48 to $14.11, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3859898,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771635,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":25110,"price":13.69,"value":343755.9,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.34 to $14.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3825338,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771634,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16841,"price":13.06,"value":219943.46,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.33, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3800228,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1772679,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-27","kind":"purchase","planned":false,"acquired":true,"shares":24504,"price":12.31,"value":301644.24,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.94 to $12.68, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3783387,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1772678,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-26","kind":"purchase","planned":false,"acquired":true,"shares":34000,"price":11.73,"value":398820.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.32 to $12.04, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3758883,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1774052,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":29967,"price":11.65,"value":349115.55,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.50 to $12.14, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3724883,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774051,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":30773,"price":10.8,"value":332348.4,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.49, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3694916,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774050,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":11.14,"value":445600.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.48, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3664143,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1776339,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2124143},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776338,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6576400},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776337,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6895021},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776336,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1144973},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776335,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":684167},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776334,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":17,"value":25500000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3624143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776333,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2124143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776332,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":11886758,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776331,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":12205379,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776330,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1144973,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776329,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":684167,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1784764,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option (right to buy)","published_at":"2023-09-08T20:24:49.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":55000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-09-07","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-048784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123048784/doc4.xml","form_type":"4"}},{"id":1810979,"issuer":{"id":110669,"kind":"organization","name":"DA32 Life Science Tech Acquisition Corp.","symbol":"DALS"},"owners":[{"id":110670,"kind":"organization","name":"ARCH Venture Fund XI, L.P.","position":1,"cik":"0001831802","reported_name":"ARCH Venture Fund XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110671,"kind":"organization","name":"ARCH Venture Partners XI, L.P.","position":2,"cik":"0001847567","reported_name":"ARCH Venture Partners XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110672,"kind":"organization","name":"ARCH Venture Partners XI, LLC","position":3,"cik":"0001847601","reported_name":"ARCH Venture Partners XI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":4,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-10T20:27:17.000Z","date":"2023-07-28","kind":"other","planned":false,"acquired":false,"shares":1600000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is filed jointly by ARCH Venture Fund XI, L.P. (\"AVF\"), ARCH Venture Partners XI, L.P. (\"AVP LP\"), ARCH Venture Partners XI, LLC (\"AVP LLC\"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the \"Reporting Persons\"). Keith Crandell has direct ownership of the Issuer's Class B Common Stock, as well as indirect pecuniary ownership of the Issuer's Class B Common Stock and shares of Class A common stock purchased in a private placement and is filing his own Form 4 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-016233","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863294/000106299323016233/form4.xml","form_type":"4"}},{"id":1849697,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-20T20:49:44.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-038445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123038445/doc4.xml","form_type":"4"}},{"id":1852720,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:49:22.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":39062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 14, 2024 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":39062,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Class A Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-23-000025","document":"wf-form4_168695215021438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000025/wf-form4_168695215021438.xml","form_type":"4"}},{"id":1858514,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T21:42:33.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023."}],"balance_after":65000,"derivative":{"exercise_price":6.7,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-23-005089","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000156218023005089/primarydocument.xml","form_type":"4"}},{"id":1879802,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:16:18.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":12054,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12054,"derivative":{"exercise_price":25.74,"exercise_date":"2024-05-22","expiration_date":"2033-05-21","underlying":"Common Stock","underlying_shares":12054},"source":{"system":"sec-edgar","filing":"0001209191-23-031882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031882/doc4.xml","form_type":"4"}},{"id":1879801,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:16:18.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":576148,"source":{"system":"sec-edgar","filing":"0001209191-23-031882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031882/doc4.xml","form_type":"4"}},{"id":2060101,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-06T21:19:19.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":1353,"source":{"system":"sec-edgar","filing":"0001562180-23-000268","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219042/000156218023000268/primarydocument.xml","form_type":"4"}},{"id":2131735,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":1,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-10-27T00:01:15.000Z","date":"2022-10-24","kind":"exercise","acquired":false,"shares":49999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the \"Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by a trust for the benefit of family members of the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16080},"source":{"system":"sec-edgar","filing":"0001628280-22-027124","document":"wf-form4_166682885724798.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828022027124/wf-form4_166682885724798.xml","form_type":"4"}}],"next_cursor":"2022-10-27T00:01:15.000000Z,2131735"}